Friday, March 14, 2025
8.1 C
London
HomeFinTechBotanix Pharmaceuticals: Passes FDA mid-cycle review for Sofpironium Bromide

Botanix Pharmaceuticals: Passes FDA mid-cycle review for Sofpironium Bromide

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...

Botanix Pharmaceuticals Passes FDA mid-cycle review for Sofpironium Bromide

  • Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review
  • The FDA detected no safety issues and no risk management issues or board requirements in the review of the Botanix product
  • BOT says it will now continue discussions with the FDA around labelling, clinical outcome assessments, patient instructions and a brand name for its product
  • The planned approval date for Sofpironium Bromide remains on track for September 2023
  • BOT has called a trading halt ahead of a planned capital raise, and shares last traded at 10 cents

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories